Should Cardiovascular Preventive Therapy Be Over-the-Counter?
- PMID: 34503681
- DOI: 10.1016/j.jacc.2021.07.020
Should Cardiovascular Preventive Therapy Be Over-the-Counter?
Keywords: Web application; consumer self-selection; nonprescription statins.
Conflict of interest statement
Funding Support and Author Disclosures Dr Pagidipati has received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eggland’s Best, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and Verily Life Sciences; and has received consulting support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. Dr Peterson has received research support from Amgen, Janssen, Bristol Myers Squibb, and Esperion; and has received consulting support from Janssen, Boehringer Ingelheim, and Cerner.
Comment on
-
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy.J Am Coll Cardiol. 2021 Sep 14;78(11):1114-1123. doi: 10.1016/j.jacc.2021.06.048. J Am Coll Cardiol. 2021. PMID: 34503680
-
A Transatlantic Comparison of Patient-Reported Access to and Use of Aspirin in Contemporary Preventive Cardiology.J Am Coll Cardiol. 2021 Sep 14;78(11):1193-1195. doi: 10.1016/j.jacc.2021.07.015. J Am Coll Cardiol. 2021. PMID: 34503688 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical